T regulatory cells (Tregs) are a specialized subset of immune cells whose primary job is to prevent your immune system from attacking your own body. They make up roughly 5 to 10% of your CD4+ T cells, a major category of white blood cells, and they act as a braking system that keeps immune responses in check. Without them, the immune system turns on healthy tissues, causing severe and often fatal autoimmune disease.
How Tregs Differ From Other Immune Cells
Most immune cells exist to ramp up a response: they detect threats, sound alarms, and attack. Tregs do the opposite. They suppress other immune cells to prevent overreaction. Think of the immune system as an accelerator and a brake working together. Tregs are the brake.
What makes a T cell a “regulatory” T cell comes down to a master control protein called FOXP3. This protein acts as a lineage marker, meaning it’s what commits the cell to its regulatory identity. The vast majority of FOXP3-positive cells are found within the CD4+ T cell population. Tregs also display high levels of a surface protein called CD25 (part of a receptor for an important immune signaling molecule called IL-2), along with elevated levels of CTLA-4, another surface protein involved in dialing down immune activation. These markers help researchers and clinicians identify Tregs, though FOXP3 remains the defining feature.
Where Tregs Come From
Tregs originate from two distinct sources. The first and best-studied pathway begins in the thymus, a small organ behind your breastbone where T cells mature. These thymic Tregs (sometimes called tTregs) are generated when developing T cells encounter fragments of the body’s own proteins and respond strongly to them. Rather than being released to attack those proteins, these cells are instead reprogrammed into regulators. The thymic medulla, the inner region of the organ, is the critical compartment where this selection happens.
The second pathway produces peripheral Tregs (pTregs), which develop outside the thymus from conventional T cells that are converted into regulatory cells in response to signals in their environment. These peripherally generated Tregs play important roles in situations where the immune system needs to tolerate something that isn’t a threat, such as during pregnancy, when the mother’s body must avoid rejecting the fetus, or in the gut, where the immune system coexists with trillions of harmless bacteria.
How Tregs Suppress the Immune System
Tregs use several strategies to keep other immune cells in line, and they can deploy more than one at a time.
- Direct cell contact. When Tregs physically touch conventional T cells, they block the calcium signaling those cells need to activate. This disruption happens almost immediately after the target cell receives its activation signal and shuts down the molecular chain reaction required for immune activation. Notably, the suppressed state persists even after the Treg is removed, meaning a brief interaction can have a lasting effect.
- Anti-inflammatory signaling molecules. Tregs release IL-10, TGF-beta, and IL-35, all of which dampen inflammation and reduce the activity of nearby immune cells.
- Starving other cells of fuel. Tregs consume large quantities of IL-2, a growth factor that other T cells need to multiply. By soaking it up, Tregs limit how aggressively other immune cells can expand.
- Killing overactive cells. In some cases, Tregs can directly kill target immune cells using the same molecular machinery (granzyme and perforin) that killer T cells use against infected cells.
These mechanisms give Tregs remarkable flexibility. They can selectively suppress certain immune functions without shutting down the entire response. For example, Tregs can block the production of specific inflammatory molecules by CD4+ T cells without necessarily stopping those cells from dividing.
What Happens When Tregs Fail
The clearest illustration of Treg importance comes from a rare genetic condition called IPEX syndrome, caused by mutations in the gene that encodes FOXP3. Because FOXP3 is what defines a Treg, children born with this mutation essentially lack functional regulatory T cells entirely. The results are devastating. IPEX typically appears in the first year of life with a triad of severe symptoms: an autoimmune attack on the intestines causing chronic watery diarrhea and malabsorption, type 1 diabetes (often within the first months of life), and widespread eczema.
Beyond this core triad, children with IPEX frequently develop autoimmune destruction of blood cells, liver inflammation, kidney disease, thyroid dysfunction, hair loss, and arthritis. Their compromised immune regulation also leaves them vulnerable to severe infections including sepsis and meningitis. Without a bone marrow transplant or aggressive immune suppression, the majority of affected boys die within the first one to two years of life from malnutrition, metabolic collapse, or overwhelming infection. IPEX is X-linked, so it almost exclusively affects males.
This condition is rare, but it proves a fundamental point: without Tregs, the immune system is incompatible with life.
Tregs in Autoimmune Disease
In more common autoimmune diseases, Tregs are present but don’t work properly. In multiple sclerosis, for instance, Tregs circulate in normal numbers but are functionally impaired. When researchers isolate these cells and test them in the lab, they show a reduced ability to suppress the proliferation of other T cells compared to Tregs from healthy people. A similar pattern appears in animal models of MS, where Tregs accumulate at inflammation sites in the brain and spinal cord but fail to control the autoimmune attack.
This functional impairment appears to be driven, at least in part, by the inflammatory environment itself. Pro-inflammatory signaling molecules produced at sites of active disease can reduce both the number and the suppressive capacity of Tregs, creating a vicious cycle: inflammation weakens Tregs, and weakened Tregs allow inflammation to continue. The anti-inflammatory molecules that Tregs rely on, particularly IL-10 and TGF-beta, have been shown to be important mediators of Treg-driven suppression in colitis, type 1 diabetes, and MS-like disease in animal models.
How Tumors Exploit Tregs
If autoimmune disease represents too little Treg activity, cancer often represents too much of it in the wrong place. Solid tumors actively recruit Tregs into their environment to shield themselves from immune attack. Tregs are found at high frequencies in the tumor tissue of many cancer types, and a high ratio of Tregs to killer T cells within a tumor is associated with a poor prognosis in the majority of solid cancers.
Tumors accomplish this recruitment by producing chemical attractants called chemokines that draw Tregs in from the bloodstream and nearby lymph nodes. One of the most well-documented is CCL22, which attracts Tregs through a receptor called CCR4. This mechanism has been identified in breast cancer, cervical cancer, brain tumors, colorectal cancer, and pancreatic cancer, among others. Higher CCL22 levels in a tumor correlate with more Treg infiltration and worse outcomes.
Once inside the tumor, Tregs can also be converted from conventional T cells or expand locally, further tipping the balance in the tumor’s favor. Some tumor-associated Tregs even develop enhanced suppressive capabilities. In colorectal cancer, for example, Tregs expressing a particular surface receptor called CCR5 are more potent suppressors than those without it, suggesting the tumor environment selects for the most effective immune inhibitors.
This understanding has made Tregs a major target in cancer immunotherapy. Strategies to selectively deplete or disable Tregs within tumors, without eliminating their protective function elsewhere in the body, are an active area of clinical development. The challenge is precision: removing Tregs broadly would risk triggering autoimmune side effects, while leaving them intact allows tumors to hide from immune surveillance.